Obeticholic acid, a first-in-class FXR agonist, has been proven to modify the liver pathological progression (steatosis, inflammation and hepatocyte ballooning, fibrosis) of NASH animal models (7, 67, 68). The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.